Alternative splicing of pre-mRNAs plays an important role in generating biological and functional diversity. Neuro-oncological ventral antigen 1 (Nova1) is a neuron-specific splicing factor which controls the alternative processing of a wide array of mRNAs important for synaptic activity. It is essential for the proper development of the mammalian motor system and for the survival of motoneurons. Since Nova1 gene contains putative regulatory AUrich elements (ARE) in its highly conserved 3' untranslated region (3'UTR), we investigated whether its expression is regulated by posttranscriptional mechanisms mediated by AREbinding proteins. Among these, the neuronal ELAV (nELAV) factors are interesting candidates, since their RNA-binding activity is necessary for neuronal differentiation and maintenance. By analysis of ribonucleoprotein complexes in vivo and in vitro we demonstrated that the Nova1 mRNA is a novel target of the nELAV proteins. We defined the nELAV binding site by functional experiments with luciferase reporter gene and Nova1 3'UTR deletion sequences. Gene silencing and over-expression of the nELAV member HuD in motoneuronal NSC34 cells indicate that Nova1 mRNA stability and translation are positively and strongly controlled by the nELAV proteins. In addition, nELAV phosphorylation by a PKCdependent pathway induces the recruitment of Nova1 mRNA to polysomes. Noteworthy, we found that nELAV proteins are also able to modulate Nova1 splicing activity on its target genes.
Alternative splicing of pre-mRNAs plays an important role in generating biological and functional diversity. Neuro-oncological ventral antigen 1 (Nova1) is a neuron-specific splicing factor which controls the alternative processing of a wide array of mRNAs important for synaptic activity. It is essential for the proper development of the mammalian motor system and for the survival of motoneurons. Since Nova1 gene contains putative regulatory AUrich elements (ARE) in its highly conserved 3' untranslated region (3'UTR), we investigated whether its expression is regulated by posttranscriptional mechanisms mediated by AREbinding proteins. Among these, the neuronal ELAV (nELAV) factors are interesting candidates, since their RNA-binding activity is necessary for neuronal differentiation and maintenance. By analysis of ribonucleoprotein complexes in vivo and in vitro we demonstrated that the Nova1 mRNA is a novel target of the nELAV proteins. We defined the nELAV binding site by functional experiments with luciferase reporter gene and Nova1 3'UTR deletion sequences. Gene silencing and over-expression of the nELAV member HuD in motoneuronal NSC34 cells indicate that Nova1 mRNA stability and translation are positively and strongly controlled by the nELAV proteins. In addition, nELAV phosphorylation by a PKCdependent pathway induces the recruitment of Nova1 mRNA to polysomes. Noteworthy, we found that nELAV proteins are also able to modulate Nova1 splicing activity on its target genes.
Our data indicate nELAV proteins as the first factors affecting the expression and activity of the neuronal splicing regulator Nova1 and, consequently, as major candidates for the physiological modulation of Nova1-dependent processing of pre-mRNAs in neurons.
Alternative RNA processing is a general mechanism to generate functionally diverse polypeptides from a single gene, being estimated that at least 74% of the human multi-exonic premRNAs undergo alternative splicing (1) . Neurooncological ventral antigen 1 (Nova1) is a neuronspecific RNA-binding protein (RBP) which regulates the alternative splicing of a set of transcripts involved in the formation and activity of the synapses (2, 3) . Nova1 null mice exhibit severe defects in the development of the motor system suggesting an essential function of this neuronal splicing factor for the survival and maintenance of motoneurons (4) . Nova1 protein is mainly localized in the ventral spinal cord and midbrain, while Nova2, the other member of the Nova RBP family, shows a different and complementary expression pattern, being involved in the control of pre-mRNA processing in other two brain regions, the neocortex and the hippocampus (5-7). Nova1 and Nova2 genes are highly homologue and phylogenetically conserved, but profoundly differ in their 3' untranslated region (3'UTR) sequences. While the long Nova1 3'UTR is well conserved in mammals (97% identity between man and mouse) and enriched in regulatory AU-rich consensus elements (ARE), the shorter Nova2 3'UTR is more variable among orthologs. These observations suggest that post-transcriptional regulation mechanisms may participate in the control of the differential expression of the two Nova genes in the nervous system. Post-transcriptional regulation mechanisms, indeed, rely on specific cis-acting elements present in the 3'UTR of target mRNAs, and on RBPs and non-coding RNAs as trans-acting factors that specifically recognize and bind such regulatory elements (8) . RBPs are important determinants of gene expression, controlling distinct steps of mRNA life such as splicing, transport, stability, translation, and degradation (9) . Together with ubiquitous factors, tissue-specific RBPs are responsible for the development and maintenance of differentiated cells and tissues, strongly influencing their proteome composition (10) . RBP-mediated post-transcriptional mechanisms are particularly relevant during embryogenesis and in highly specialized cells such as neurons, because they allow a precise spatio-temporal control of gene expression, a subcellular compartmentalization of mRNAs, and a fast modulation of mRNA translation. The great potentiality and complexity of these regulatory processes are well described by the posttranscriptional operon or RNA regulon model (8, 11) . In this model the fate of a single mRNA may be predicted to be differentially and combinatorially controlled by specific and dynamic sets of RBPs in distinct cell conditions and/or developmental stages, as clearly verified in yeast (12) .
Among the trans-acting factors potentially involved in the post-transcriptional control of Nova1 gene expression, we identified the highly conserved ELAV (embryonic lethal abnormal vision system) proteins as interesting candidates in the nervous system. In mammals the three ELAV family members, HuB, HuC, and HuD, are selectively expressed in neurons, while the fourth member, HuR, is ubiquitous (13) . ELAV RBPs act as mRNA stabilizing factors and translational enhancers by binding to AREs in the 3'UTR of target mRNAs which are usually characterized by high turnover rates (14,15). Different target transcripts of the three neuron-specific ELAV (nELAV) proteins have been identified in the nervous system, such as GAP43 (16) , Mapt (17), NF-M (18), AchE (19) , and Msi-1 (20) . In different cell models, nELAV proteins have been shown to be necessary and sufficient to induce neuronal differentiation (21) . This function was also confirmed in HuD null mice by the demonstration that this RBP plays a critical role in regulating the self-renewal capacity and neuronal differentiation of neural stem cells (22) . Importantly, also neuronal plasticity and memory formation processes have been shown to be dependent on nELAV RNA-binding activities in the hippocampus (23) (24) (25) .
In this paper we investigated whether the neuronal splicing factor Nova1, which is essential for motoneuron survival, is a target of the AREbinding proteins nELAV. In the motoneuronal cell line NSC34 we show that nELAV proteins bind and post-transcriptionally regulate Nova1 mRNA, increasing its stability and translation and, most importantly, modulating Nova1 activity as a splicing factor.
Experimental procedures
NSC34 cell culture and treatments-The motoneuronal cell line NSC34 (a kind gift of N.R. Cashman, University of British Columbia, Vancouver, Canada) was cultured in DMEM supplemented with 5% fetal bovine serum, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 µg/ml streptomycin. Transient and stable transfections were perfomed with Lipofectamine Plus (Invitrogen) following the manufacturer's instructions. Puromycin (1 µg/ml) was used for selection and maintenance of stable shRNA transfectants. Neurite length was measured using QWin Plus 3.3 software (Leica Microsystems) on five independent images for a total of more than 600 cells per condition. NSC34 cells were exposed to 50 µM 5,6-dichlorobenzamidazole riboside (DRB), 100 nM phorbol 12-myristate-13-acetate (PMA) or to the solvent (DMSO) alone for the indicated time. All reagents were purchased from Sigma.
mRNP isolation and immunoprecipitationIsolation of endogenous mRNPs was conducted as already described (20) . Briefly, 5x10 6 NSC34 cells were harvested and resuspended in RNP buffer (100 mM KCl, 5 mM MgCl 2 , 10 mM HEPES pH 7.4, 0.5% NP-40, 10 µM DTT) plus a protease inhibitory cocktail (Roche). NSC34 lysates (350 µg) were incubated in NT2 buffer (50 mM TrisHCl pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, 20 mM EDTA, 0.05% NP-40) together with protein G Sepharose-beads (GE Healthcare) precoated with 5 µg of the pan neuronal ELAV (16A11, Invitrogen) or the isotypic IgG (Santa Cruz Biotechnology) antibody. An aliquot (10%) of the reaction mix was collected as the initial input for sample normalization and total RNA was then extracted by TRIzol reagent (Invitrogen) according to manufacturer's recommendations. mRNAs were phenol-cloroform extracted from immunoprecipitated mRNPs after digestion with proteinase K for 30 minutes, retrotranscribed and quantitated by real time PCR. Data were analyzed as previously reported (20) .
Real time quantitative PCR-mRNA retrotranscription was performed after DNaseI (Roche) treatment using SuperScriptII RT (Invitrogen) and oligodT primers. . Plasmid constructs-Nova1 3'UTR full-length (FL) and deletion fragments were RT-PCR amplified from mouse total brain RNA and cloned in pCRII vector (Invitrogen). For luciferase activity assays, Nova1 A1 deletion fragments were XbaI cloned 3' of the Renilla reporter gene in the pGL4.71P vector (Promega). For shRNA gene silencing assay, a double stranded oligonucleotide complementary and specific for murine HuD sequence was BglII/HindIII cloned into the pSUPER.retro vector modified in the linker region (a kind gift of G. Pelicci, IEO, Milan, Italy). All primer sequences are reported in Supplementary Table 2. All clones and their orientation were validated by sequencing. Single nELAV cDNAs and the corresponding recombinant proteins were obtained as previously described (20) . The pEGFP-HuD plasmid containing the human HuD cDNA was a kind gift of N.I. Perrone-Bizzozero (University of New Mexico, Albuquerque, NM).
In vitro transcription, REMSA and UV crosslinking-Radiolabelled riboprobes were obtained by transcribing 0.5 µg restriction enzymelinearized construct DNA in presence of 20 µCi α-[ 32 P]UTP as already described (20) . The resulting riboprobes were purified on ProbeQuant G-50 microcolumns (GE Healthcare).
For REMSA experiments, 300,000 cpm 32 Plabelled riboprobe were incubated with 10 ng of each recombinant nELAV protein for 10 minutes at room temperature in 25 µl of binding buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.4, 1.5 mM MgCl 2 , 0.5 mM DTT, 5% glycerol, and 0.5 µg/µl tRNA). For competition assays, 2-and 4-fold excess of unlabelled RNA was pre-incubated for 20 minutes with a mixture of the three recombinant nELAV proteins prior to the addition of the radioactive Nova1 riboprobe. Samples were then run on a 5% PAGE in TBE buffer and visualized by autoradiography.
UV cross-linking and immunoprecipitation experiments were performed as previously described (20) using the pan neuronal ELAV (Invitrogen) or the irrelevant IgG antibody.
HEK293T cell culture and luciferase assayHuman embryonic kidney (HEK) 293T cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin. For each experimental condition, 300,000 cells were plated in duplicate and transfected using 2µl Lipofectamine Plus and 200 ng of each construct (Renilla-A1 subclones and pEGFP-HuD) and 200 ng of firefly reporter vector (pGL3P, Promega). Measurement of the luciferase activity was performed using the Dual Luciferase Reporter Assay System (Promega) 24 hours after transfection. The Renilla luciferase activity of the Nova1 3'UTR constructs was normalized against the firefly luciferase output.
Protein extraction, immunoprecipitation, and western blotting-Total mouse brain and NSC34 cells were homogenized in lysis buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.4, 1% Triton X-100, protease inhibitor cocktail). Samples were centrifuged at 12,000 x g for 15 minutes at 4°C and supernatants were collected. Proteins from different cell fractions were obtained as previously described (26) . Proteins were resolved on 10% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted with Nova1 (Upstate Biotechnology), PKCα (Transduction Laboratories), HuR, α-tubulin, phosphothreonine (Santa Cruz Biotechnology), and phosphoserine (Sigma) antibodies. The capability of the HuR antibody to detect also nELAV proteins was tested on tissues of different origin ( Figure S1 in Supplemental data). Densitometric analyses were performed with QuantityOne software (BioRad).
Analysis of alternative splicing isoforms-Total RNA, isolated from NSC34 stable transfectants using TRIzol reagent, was treated with DNaseI and retrotrascribed as described above. The obtained cDNA was quantified by real time PCR using primers for the housekeeping Rpl10a gene so that an equal amount for each sample was employed in the subsequent PCR amplification. Primers for Neogenin and JNK2 splicing isoforms were designed as previously reported (27, 28) . 50 pmoles of each forward primer were radiolabelled with 20 µCi γ-[
32 P]dATP and 10U T4 polynucleotide kinase (Roche). PCR amplification was then performed using 300 nM of each primer and Taq Gold DNA polymerase (Applied Biosystem) for 25-30 cycles. Amplicons were run on 6% PAGE in TBE buffer and dried gels were visualized by autoradiography. For detection of JNK2 splicing isoforms, PCR products were digested with RsaI restriction enzyme (Roche) prior PAGE as described (28) .
Isolation of polysomes-Polysomes were isolated from 1x10 7 NSC34 cells by a sucrose discontinuous density gradient (1.3/1.9/2.5 M) as described (29) . After ultracentifugation at 90,000 x g for 5 hours, the 1.3/1.9 M interface representing the polysomal fraction was collected. Sample was then diluted in gradient buffer (150 mM KCl, 50 mM Tris-HCl pH 7.4, 5 mM MgCl 2 ) and ultracentrifuged at 100,000 x g for 8 hours. Total RNA was immediately isolated from the final pellet using TRIzol reagent.
Immunofluorescence-Cells were fixed with 4% paraformaldehyde in PBS (pH 7.4) for 20 minutes, blocked with 10% normal goat serum (Invitrogen) and permeabilized with 0.3% Triton X-100. The pan neuronal ELAV (1:40) and Nova1 (1:500) antibodies were used for 70 minutes at 37°C and detected by Cy2-and Cy3-coniugated secondary antibodies (Jackson ImmunoResearch Laboratories). Nuclei were visualized by 4'-6-Diamidino-2-phenylindole (DAPI) staining. As a negative control, primary antibodies were replaced by normal goat serum. Slides were mounted with Fluorsave (Calbiochem) and acquired by optical (DMIRE2/HCS, Leica Microsystems) and confocal (CS SP2 AOBS, Leica Microsystems) microscopes.
RESULTS
nELAV proteins associate with Nova1 mRNA in vivo. The murine Nova1 3'UTR sequence is very long (5.4 Kb) and is 97% identical to the shorter 1.9 Kb-long human ortholog. This highly conserved region contains putative ARE signatures scattered along the entire sequence. Its secondary structure was predicted by the Sfold algorithm (30) to be very stable (-505 kcal/ mol) and hairpin-rich (data not shown), suggesting the potential binding of trans-acting regulatory factors.
We used a ribonomic approach described by Tanenbaum et al (31) to isolate ribonucleoprotein (mRNP) complexes that physiologically form in live cells. To examine whether nELAV proteins and the Nova1 transcript are associated in the motoneuronal NSC34 cells, nELAV-containing mRNP complexes were selectively immunoprecipitated with a pan-neuronal antibody recognizing the three nELAV RBPs HuB, HuC and HuD. The co-precipitated mRNAs were isolated and the presence of the Nova1 transcript was tested by real time PCR quantitation. Nova1 mRNA was enriched by 5.1 folds in the nELAVcontaining mRNP complexes in comparison to the control sample immunoprecipitated by the irrelevant IgG antibody (Fig. 1) . We tested the presence of other two well-known nELAV targets, GAP43 and Mapt, and we observed the enrichment of their transcripts by 3.9 and 2.9 folds, respectively. These data confirm that nELAV mRNP particles were specifically isolated in the assay. Conversely, the fact that the abundant Rpl10a mRNA, whose 3'UTR sequence has no evident ARE signature, was not enriched in nELAV-containing mRNPs clearly indicates that Nova1 transcript is specifically associated to nELAV proteins in motoneuronal NSC34 cells.
Nova1 3'UTR is a target of the ARE-binding proteins nELAV.
We have shown that nELAV RBPs specifically interact with Nova1 mRNA in vivo. To demonstrate that nELAV binding is dependent on Nova1 3'UTR sequence, we performed RNA electrophoretic mobility shift assays (REMSA) using recombinant proteins for each nELAV RBP and, as radiolabelled riboprobe, the highly conserved 1.9 Kb-long fragment (FL) of mouse Nova1 3'UTR. A RNA-protein complex clearly formed with all the three nELAV RBPs, but not with the GFP protein used as a negative control ( Fig. 2A) . nELAV specific binding to Nova1 was further tested in competition experiments, where increasing amounts of unlabelled Nova1 3'UTR mRNA were able to affect the formation of radiolabelled mRNP complexes (Fig. 2B) . The specificity of Nova1 mRNA-nELAV protein interaction was also confirmed when an excess of an unrelated and unlabelled RNA probe was used. In this case no effect on the formation of the Nova1-nELAV mRNP complex was observed in REMSA experiments (Fig. 2C) .
Functional mapping of nELAV binding to Nova1 3'UTR. To identify the Nova1 sequence responsible for nELAV protein binding, we performed UV cross-linking and immunoprecipitation assays with different deletion fragments of the Nova1 FL 3'UTR used in REMSA experiments (Fig. 3A) . Two partially overlapping fragments, A and B (about 1.1 Kb in lenght), were used as radiolabelled riboprobes in the presence of mouse brain protein lysate. GAP43 3'UTR mRNA was employed as a positive control in the assay. After selective immunoprecipitation of nELAV-containing mRNPs and SDS-PAGE of the stably formed radiolabelled complexes, a positive band was visualized with fragment A (Fig. 3B) . To better map the Nova1 A binding region, two smaller fragments, A1 and A2, were subsequently used in the assay and only A1 riboprobe was shown to be responsible for nELAV protein binding. The computational analysis of this 435nt-long sequence revealed the presence of 5 scattered putative AREs, of whom only one shows the canonical AUUUA sequence (Fig. S2 in Supplementary data). We therefore generated three smaller deletion fragments according to the distribution of the predicted AREs and used them in UV cross-linking/immunoprecipitation experiments. Only the 213 bp-long deletion fragment A1 221-435 revealed a positive binding to nELAV proteins (Fig. 3B) .
To test whether nELAV binding to this region had also functional relevance, we performed a luciferase assay using the three different Nova1 A1 deletion sequences inserted into the unique XbaI cloning site at the 3' of the Renilla reporter gene. Since the A1 221-435 fragment contained a XbaI recognition site, we obtained and cloned a smaller 123bp-long fragment (A 221-345 ), in which one of the three predicted AREs was excluded (Fig. S2 in Supplemental data). We used the human HEK293T cells because they do not express the nELAV proteins, as we could assess by Western blot analysis (data not shown). After transient transfection with the Renilla-A1 constructs, we measured the changes of luciferase activity following expression of the pEGFP-HuD plasmid containing the human HuD cDNA. We found that only the shorter A1 221-345 3'UTR sequence could increase the reporter luciferase activity by 1.7 fold when the pEGFP-HuD was transfected into HEK293T cells (Fig. 3C) .
We thus identified the 123nt-long sequence of Nova1 3'UTR as the region responsible for the binding of the trans-acting factors nELAV. This region contains a group V ARE sequence (AUUUA) according to ARE database (ARED; 32) followed by a non canonical AUUUUA sequence with a 7nt GC-rich stretch in between. The secondary structure prediction of A1 fragment showed the formation of a loop corresponding to the canonical ARE contained in the A1 221-345 sequence, while the non-canonical one was folded in a less exposed stem structure (data not shown).
HuD gene silencing affects Nova1 protein content. In vivo and in vitro experiments indicate that nELAV proteins are able to specifically bind the ARE-containing Nova1 3'UTR. In order to obtain functional data about the role of nELAV proteins in regulating post-transcriptionally Nova1 gene expression, we designed a complementary sequence specific to murine HuD mRNA (shHuD) to silence its expression in NSC34 cells by a short hairpin RNA (shRNA) plasmid-based technology. After isolation of stable transfectants, examination of shHuD cell morphology revealed a marked phenotypic change with a prominent loss of spontaneous neurite outgrowth and arborization in comparison to both parental and mock-transfected NSC34 cells (Figs. S3A-C in Supplementary data). We found that the proportion of short neuritebearing cells was significantly increased in shHuD stable transfectants compared to parental and control cells. On the contrary, the sub-populations presenting longer neuronal processes significantly diminished in shHuD cells (Fig. S3D in Supplementary data ).
We evaluated the effective HuD gene silencing in the selected shHuD clone by real time RT-PCR and Western blot analyses. Besides the 55% downregulation of HuD mRNA level, we found that also HuB and HuC gene expression was greatly decreased (Fig. 4A) . To assess whether such down-regulation was selectively restricted to the nELAV transcripts, we evaluated the expression of the ubiquitous HuR and TIA-1 RBP mRNAs. HuR was only partially affected in shHuD cells, while no change in the level of the abundant ELAVrelated TIA-1 RBP was observed. In line with the mRNA data, Western blot assay confirmed that the amount of nELAV proteins was also consistently decreased in shHuD in comparison to parental and control cell lysates (Fig. 4B) .
We then investigated the effect of HuD gene silencing on Nova1 gene expression by measuring its protein level. Noticeably, we found that the content of Nova1 protein was significantly reduced to 53.5% in shHuD compared to parental NSC34 cells (Figs. 4C & 4D) . (Fig. 4C) . The human HuD cDNA of the pEGFP-HuD construct has two-base pair difference with the murine shRNA target sequence. The effective expression of pEGFPHuD mRNA and the absence of its inhibition by the shRNA construct in shHuD cells were confirmed by RT-PCR using oligonucleotides encompassing the pEGFP vector and the human HuD cDNA sequence (Fig. S4, Supplementary  data) .
These functional assays show that nELAV RBPs act as strong determinants of Nova1 protein content through post-transcriptional regulation of its mRNA.
Nova1 splicing activity depends on nELAV protein level. After finding that Nova1 protein content is strictly dependent on the upstream levels of the trans-acting factors nELAV, we examined whether such nELAV-mediated posttranscriptional regulation is also able to affect the splicing activity of Nova1 RBP on its target premRNAs. The neuron-specific processing of JNK2 and Neogenin genes has been previously shown to be controlled by Nova1 in the mouse brain (28). We studied and compared the alternative splicing pattern of these two genes in shHuD and mocktransfected motoneuronal NSC34 cells by performing RT-PCR assays with radiolabelled oligonucleotides. The predominant splicing variant of both tested genes was the unexpected nonneuronal one in mock-transfected (Fig. 5) as well as in parental cells (data not shown). When we determined the JNK2 gene splicing pattern in shHuD cells, we found that the neuron-specific isoform, containing exon 6a, decreased compared to the control clone (12% vs 37%, respectively).
The ratio between the two spliced isoforms changed and returned to be similar to the control clone when the pEGFP-HuD plasmid was transiently transfected to restore HuD gene expression (Fig. 5A) . Conversely, when we analyzed the Neogenin splicing pattern, we found that the neuronal isoform was significantly increased in shHuD cells compared to control (56% vs 27%, respectively) (Fig. 5B) . Again, HuD gene expression in shHuD cells re-established the original splicing pattern present in the mocktransfected clone. We also observed that HuD gene re-expression determined a consistent increase of the amount of all the splicing variants of both JNK2 and Neogenin genes.
These data show that nELAV proteins are able to influence indirectly the splicing activity of Nova1 RBP on its target pre-mRNAs by controlling Nova1 gene expression and protein content at post-transcriptional level.
nELAV RBPs act as stabilizing factors on Nova1 mRNA. We studied the degradation rate of the endogenous Nova1 mRNA in NSC34 cells in condition of transcriptional arrest induced by DRB, a compound able to specifically block RNA polymerase II activity. The content of Nova1 mRNA was monitored in a 8-hour time course in parental, control, and shHuD cells. As reported in Fig. 6 , Nova1 mRNA degradation kinetics was faster in shHuD cells in comparison to both parental and control cells. Indeed, Nova1 mRNA half-life was 2.95 hours in shHuD cells, while in parental and mock-transfected cells it was 4.37 and 4.95 hours, respectively. When the shHuD cells were transiently transfected with the pEGFPHuD plasmid, the decay rate of Nova1 transcript decreased showing a half-life of 11.24 hours.
These results clearly indicate that nELAV RBPs act as stabilizing factors on Nova1 mRNA, as already described for other documented nELAV targets (21) .
PKC-α activation induces nELAV protein phosphorylation and increases Nova1 mRNA translation.
We have previously shown that in human neuroblastoma SH-SY5Y cells protein kinase C (PKC) agonists, such as phorbol esters (PMA) and bryostatin, induce the phosphorylation of nELAV RBPs and the translation of the GAP43 mRNA in an nELAV-dependent way (33) .
Treatment of NSC34 cells with PMA for 10 minutes determined the translocation of the PKC-α protein from the cytosolic to the membrane and cytoskeletal fractions (Fig. 7A) . We evaluated the phosphorylation state of nELAV proteins after PMA treatment by selective immunoprecipitation with phosphothreonine and phosphoserine antibodies. A consistent and specific increase of threonine phosphorylation was observed for nELAV RBPs, since HuR protein was unaffected (Fig. 7B) . No change in the amount of phosphoserine residues was detected (data not shown). The total amount of nELAV proteins remained unchanged (Fig. 7C) , therefore confirming the specific increase of their phosphorylated threonine residues after PKC-α activation. These results are in line with our previous data obtained in human neuroblastoma cells (33) .
In this short time frame, PMA treatment also determined a significant increase (57%) of Nova1 protein steady-state levels (Fig. 7D ). In the attempt to estimate the contribution of post-transcriptional regulation to this increase, transcriptional arrest was induced by a 30-minute exposure of NSC34 cells to DRB before PMA treatment. Again, we measured a significant up-regulation (38%) of the amount of Nova1 protein, thereby excluding a major transcriptional contribution to the observed effect. Indeed, PMA treatment was shown to determine a 1.8-fold increase in Nova1 mRNA levels, although with no statistical significance (Fig. 7E) . However, since DRB completely abolished this PMA-dependent Nova1 mRNA upregulation, the increase of Nova1 protein content after PKC stimulation should be attributed mainly to post-transcriptional events. Any significant contribution of increased Nova1 mRNA stability should be excluded at 10 minutes, given the halflife of 4.37 hours for Nova1 mRNA in NSC34 cells (see Fig. 6 ). So we focused on the hypothesis of increased Nova1 mRNA polysomal loading.
We isolated the polysome fraction from NSC34 cells after PMA treatment in condition of transcriptional arrest, and changes in Nova1 mRNA engagement in translation were measured by real time RT-PCR. Our results revealed a significant 47% increase of Nova1 mRNA content in the polysome fraction after this short time of PMA treatment (Fig. 7F) , while the association to polysomes of the abundant GAPDH mRNA, which is devoid of regulatory AREs in its 3'UTR, did not change after PKC activation.
The Nova1 RBP is localized in neurites in NSC34 cells. We have shown that Nova1 gene expression is under the control of posttranscriptional regulatory mechanisms mediated by nELAV RBPs. We investigated the subcellular localization of Nova1 and nELAV proteins in NSC34 cells. According to its function as a splicing factor, immunostaining assays revealed a main distribution of Nova1 in the nuclei and in large Cajal-body-like granules. Interestingly, a diffuse and granular localization of Nova1 protein was also observed in the cytoplasm and neurites of NSC34 cells (Figs. 8A & 8D) with an overlapping expression pattern with nELAV RBPs (Figs. 8B &  8E) . However, confocal imaging suggested coexpression, but not colocalization, of Nova1 and nELAV proteins in neurites (Figs. 8C & 8F) .
To examine the possible interaction between these RBPs, coimmunoprecipitation experiments were carried out. No coprecipitation of these neuronal RBPs was detected in NSC34 cells lysates using both nELAV and Nova1 antibodies (data not shown), confirming the confocal imaging data.
DISCUSSION
In the mammalian nervous system alternative processing of pre-mRNAs is a very important regulatory mechanism as it allows to modulate protein composition according to different stimuli and conditions (34) . In particular, alternative splicing of neuron-specific isoforms actively participates in creating and maintaining the architectural and functional complexity of the brain (35) . Nonetheless, few neural factors regulating alternative splicing have been identified and characterized so far. One such neuron-specific splicing factor is Nova1, whose activity has been shown to be necessary for the development of the motor system and the survival of motoneurons (4) .
Since Nova1 controls the alternative splicing of a wide array of pre-mRNAs involved in the formation and activity of the synapses, we expect its gene expression to be tightly regulated. Gene expression is first determined by transcription factors, but post-transcriptional mechanisms triggered by RBPs and miRNAs have recently revealed to be essential to guarantee its fast, precise and complex regulation in the brain (36) . The presence of several putative AREs in the highly conserved 3'UTR of the mammalian Nova1 genes suggests that post-transcriptional mechanisms mediated by ARE-binding proteins may control Nova1 mRNA stability and translation. We speculate that the differential evolutionary conservation of the Nova1 and Nova2 3'UTR sequences might well reflect the distinct expression pattern and function of these two genes in the mammalian brain. Among the possible ARE-binding proteins regulating Nova1 mRNA at post-transcriptional level, the ELAV family is of great interest since three out of the four members are specifically expressed in neurons with an overlapping pattern to Nova1 in the spinal cord (4, 37, 38) . In this paper we have demonstrated that the neuronal ELAV (nELAV) mRNA-stabilizing RBPs specifically recognize and bind Nova1 3'UTR in an ARE-containing 123nt-long region.
By performing HuD gene silencing experiments in the motoneuronal NSC34 cells, we observed marked alterations in cell morphology, as already demonstrated in vitro for other neuronal cell models and in HuD null mice (13) . These data clearly suggest that nELAV proteins are important for neuronal differentiation and neurite outgrowth also in motoneuronal cells. Interestingly, we observed that the HuD-specific gene silencing also decreased the expression of the other two nELAV members, HuB and HuC, but not of the ubiquitously expressed HuR and TIA-1 mRNAs. This suggests the existence of auto-regulatory mechanisms that, in a crossed manner, may control the expression of all neuronal members of this RBP family in the brain. This auto-regulatory mechanism has already been described for HuB and for the elav gene in Drosophila,whose AREcontaining transcripts are controlled by their own gene products (39) (40) (41) . Interestingly, it has been recently demonstrated that several ubiquitous RBPs, including HuR, reciprocally influence and regulate post-transcriptionally their expression in a complex crossed-auto-regulatory network (42) .
The important finding is that HuD gene downregulation caused a consistent decrease of Nova1 protein level. The demonstration that this effect on Nova1 was due to the activity of nELAV proteins came from the observation that the re-expression of HuD gene in shHuD cells was able to restore Nova1 protein content. The molecular explanation of this effect is that nELAV RBPs act as stabilizing factors on Nova1 mRNA, whose turnover rate we showed to be inversely correlated to the expression level of nELAV proteins.
Our data also provide suggestive evidence that nELAV proteins favor the translation of the bound Nova1 target transcript. A direct association of nELAV RBPs to ribosomes and the translating machinery has been previously documented (18, 25) . Furthermore, activation of nELAV proteins by a PKC-dependent pathway determines their translocation to the cytoskeletal compartment (20, 33) , which has been shown to be important for the interaction with the translational apparatus (43). In NSC34 cells we observed that the acute (10 minutes) PKC-mediated phosphorylation of nELAV proteins was associated to a specific recruitment of Nova1 mRNA to the polysomal fraction. We can be confident that this is a mere post-transcriptional regulation of the Nova1 transcript because we prevented the effects of PMA, a classical PKC-activator, on the transcriptional activity by using a specific chemical inhibitor of RNA polymerase II. Therefore the observed early increase of Nova1 protein content is basically dependent on the increased availability of its mRNA to ribosomes, although some indirect PMA effects on the stability of Nova1 protein itself can not be completely excluded. Taken together, our results are strongly in agreement with a direct positive effect of activated nELAV proteins on Nova1 mRNA translatability.
It is noteworthy to observe that the nELAVdependent regulation of Nova1 gene expression is also able to influence its function as a splicing factor. In fact, the splicing patterns of two Nova1 target pre-mRNAs were found to be altered following Nova1 down-regulation in shHuD cells. We observed an opposite effect on the splicing of the two neuronal-specific isoforms of JNK2 and Neogenin genes. This phenomenon may in part be explained by the experimental cell model we used, which is embryonic in origin, while previous data on Nova1 splicing activity were obtained from the post-natal neocortex of Nova null mice (28) . Moreover, we speculate that the decrease of Nova1 protein has distinct or opposite effects on different transcripts depending on the specific RBPs required for their processing. Indeed, the neuron-specific splicing of pre-mRNAs is regulated in various neuronal cell populations by different RBPs which have complementary, additive or even competitive functions, as already demonstrated for brPTB and Nova1 (44) .
The fact that HuD gene re-expression in shHuD cells was able to completely restore the splicing patterns of JNK2 and Neogenin genes may be directly associated to the nELAV-mediated upregulation of Nova1 protein content by increased Nova1 mRNA stability and translatability. Interestingly, in condition of HuD over-expression, we also observed an overall increase of the JNK2 and Neogenin spliced isoforms. This finding seems to correlate with the presence of putative AREs in the 3'UTR of these genes (unpublished observations), indicating a possible nELAV-dependent stabilizing effect also on Nova1 target mRNAs.
Our data on Nova1 protein localization in NSC34 neurites suggest the fascinating hypothesis that Nova1 RBP may have an additional role to its well documented splicing activity, and may also be involved in the transport or translational control of target mRNAs. Although further evidence needs to be gained from in vivo studies, this possibility is not so remote. It is known from the literature that a single RBP may have multiple functions related to the mRNA metabolism, as in the case of the nELAV proteins themselves, which are known to be involved in mRNA stabilization and translation as well as in splicing and transport activities (17, 45, 46) . In particular, in motoneurons the SMN mRNP complex, responsible for the assembly and function of the splicing machinery, is also involved in the axonal transport of mRNAs (47) .
All our results confirm that post-transcriptional mechanisms mediated by nELAV proteins exert a pivotal neurobiological role in the control not only of Nova1 mRNA stability and translation but, importantly, also of its splicing function. We have shown that a change in nELAV protein abundance may dramatically affect the correct processing of Nova1 target pre-mRNAs, with potential longterm consequences on the overall metabolism and activity of neurons. Our data are the first ones identifying post-transcriptional factors that can effectively modulate Nova1 RBP abundance and splicing activity in the nervous system, although we suppose that such regulation is more complex and likely requires the competitive and/or synergic action of other RBPs and miRNAs.
In conclusion, here we have functionally correlated two important classes of neuronspecific RBPs, nELAV and Nova, which interestingly represent the autoantigens of two distinct paraneoplastic neurologic syndromes, encephalomyelitis and POMA, respectively (48, 6) . The identification of nELAV proteins as pivotal post-transcriptional regulators of Nova1 gene expression and activity may help elucidate the molecular mechanisms underlying the neurobiology of highly specialized cells such as motoneurons. The function of nELAV proteins in motoneurons has never been investigated so far, even if their expression has been observed in the ventral spinal cord in vertebrates (37, 49) . These findings also suggest that alterations in the nELAV-mediated post-transcriptional regulatory mechanisms may severely affect the survival of motoneurons and, eventually, contribute to the development of motoneuron diseases in humans. Fig. 1 . Analysis of endogenous nELAV-containing mRNPs in NSC34 cells. The selective immunoprecipitation of nELAV-mRNP complexes was conducted on NSC34 cell lysates using the pan neuronal ELAV antibody (16A11). The isotypic IgG antibody was used as a control. Coprecipitated transcripts were quantified by real time RT-PCR assay with specific primers for Nova1, GAP43, Mapt, and Rpl10a genes. For each immunoprecipitated sample, normalization was conducted on the mRNA amount of each gene in the initial lysate. Fold change was calculated versus the control IgG antibody. Values are expressed as mean and s.e.m. (n=4; one-way ANOVA and Tukey post hoc test; * p<0.05, ** p<0.01). Fig. 2 . nELAV proteins specifically bind Nova1 mRNA. A. The three recombinant neuronal proteins HuB, HuC, HuD were used in REMSA assays with 32 P-labelled riboprobe corresponding to the murine Nova1 3'UTR sequence (FL, 1895 nt) highly homologous to the human one (see also Figure 3A ). Green fluorescent protein (GFP) was used as a negative control (lane 1).
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B & C.
Competition experiments were performed using a mix of the three HuB, HuC, HuD proteins (nELAV). As competitors, increasing amounts (2x, 4x) of Nova1 unlabelled riboprobe (lanes 2 and 3 in B, respectively) and of the irrelevant tRNA probe (lanes 2 and 3 in C, respectively) were used. Arrowhead indicates the retarded migration of the Nova1 mRNA/nELAV protein complex; asterisk shows free Nova1 riboprobe. Representative western blots of Nova1 and ELAV proteins in parental, mock, and shHuD cells, and in shHuD clone after transfection with pEGFP-HuD vector (shHuD+HuD). The specificity of the ELAV antibody used in western blot was first assessed on lysates from different tissues ( Figure S1 in Supplementary data). α-tubulin is used for sample normalization. D. Densitometric analyses of Nova1 western blot data normalized to α-tubulin (mean and s.e.m.; n=4; one-way ANOVA and Tukey post hoc test; * p<0.05, ** p<0.01). Fig. 5 . The splicing activity of Nova1 is altered in shHuD cells. The splicing patterns of (A) JNK2 (exon 6) and (B) Neogenin (exon 27) genes were analyzed by radiolabelled RT-PCR and autoradiography. A representative gel is shown (left panels) and the relative amount of the splicing isoforms in control (mock), shHuD, and shHuD+HuD cells is visualized in graph (right panels, mean and s.e.m.; n=4). An equal amount of cDNA was used for each amplification reaction after quantitation of the housekeeping Rpl10a transcript in real time PCR experiments. Fig. 6 . Nova1 mRNA degradation kinetics depends on nELAV protein levels. Nova1 mRNA content was quantified by real time PCR in parental (par), control (mock), shHuD and shHuD+HuD cells after 2, 4, 6, and 8 hours of transcriptional arrest by DRB treatment. Nova1 mRNA amount at each time-point was compared to the initial mRNA level (100%). A nonlinear regression analysis was conducted, which gave a first order decay constant (k; mean and s.e.m.; n=6). Average mRNA halflife (t 1/2 ) was calculated as 0.69/k and reported in the table (** p<0.01 versus both parental and mock). 
